JP2005533804A - システイン・プロテアーゼ活性に関係する疾患を処置するための新規プリン−もしくはピロール−［２，３−ｄ］ピリミジン−２−カルボニトリル - Google Patents
システイン・プロテアーゼ活性に関係する疾患を処置するための新規プリン−もしくはピロール−［２，３−ｄ］ピリミジン−２−カルボニトリル Download PDFInfo
- Publication number
- JP2005533804A JP2005533804A JP2004515329A JP2004515329A JP2005533804A JP 2005533804 A JP2005533804 A JP 2005533804A JP 2004515329 A JP2004515329 A JP 2004515329A JP 2004515329 A JP2004515329 A JP 2004515329A JP 2005533804 A JP2005533804 A JP 2005533804A
- Authority
- JP
- Japan
- Prior art keywords
- carbonitrile
- chlorophenyl
- purine
- alkyl
- morpholin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108010005843 Cysteine Proteases Proteins 0.000 title claims abstract description 13
- 102000005927 Cysteine Proteases Human genes 0.000 title claims abstract description 13
- 201000010099 disease Diseases 0.000 title abstract description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract description 8
- 230000000694 effects Effects 0.000 title abstract description 5
- IIHQNAXFIODVDU-UHFFFAOYSA-N pyrimidine-2-carbonitrile Chemical compound N#CC1=NC=CC=N1 IIHQNAXFIODVDU-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract description 51
- 229910052717 sulfur Inorganic materials 0.000 claims abstract description 21
- 108090000613 Cathepsin S Proteins 0.000 claims abstract description 11
- 102100035654 Cathepsin S Human genes 0.000 claims abstract description 11
- 238000004519 manufacturing process Methods 0.000 claims abstract description 6
- 125000000217 alkyl group Chemical group 0.000 claims description 38
- 229910052739 hydrogen Inorganic materials 0.000 claims description 27
- 239000001257 hydrogen Substances 0.000 claims description 26
- -1 amino, hydroxy Chemical group 0.000 claims description 21
- 150000002431 hydrogen Chemical class 0.000 claims description 20
- 229910052760 oxygen Inorganic materials 0.000 claims description 20
- 150000003839 salts Chemical class 0.000 claims description 17
- 229910052757 nitrogen Inorganic materials 0.000 claims description 16
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 14
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 13
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 12
- 238000000034 method Methods 0.000 claims description 12
- 229920006395 saturated elastomer Polymers 0.000 claims description 12
- 125000003118 aryl group Chemical group 0.000 claims description 10
- CDLFCUGNXCSXKZ-UHFFFAOYSA-N 7-(4-chlorophenyl)-4-morpholin-4-ylpyrrolo[2,3-d]pyrimidine-2-carbonitrile Chemical compound C1=CC(Cl)=CC=C1N1C2=NC(C#N)=NC(N3CCOCC3)=C2C=C1 CDLFCUGNXCSXKZ-UHFFFAOYSA-N 0.000 claims description 9
- 229910052736 halogen Inorganic materials 0.000 claims description 9
- 125000001072 heteroaryl group Chemical group 0.000 claims description 9
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 claims description 9
- 125000003545 alkoxy group Chemical group 0.000 claims description 8
- 239000008194 pharmaceutical composition Substances 0.000 claims description 8
- 150000002367 halogens Chemical class 0.000 claims description 7
- 230000005764 inhibitory process Effects 0.000 claims description 7
- 125000004527 pyrimidin-4-yl group Chemical group N1=CN=C(C=C1)* 0.000 claims description 7
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 6
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 6
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 6
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 6
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 6
- 241001465754 Metazoa Species 0.000 claims description 5
- 239000003814 drug Substances 0.000 claims description 5
- KJGSMDDJESIJNG-UHFFFAOYSA-N 6-(4-chloroanilino)-9-ethylpurine-2-carbonitrile Chemical compound N1=C(C#N)N=C2N(CC)C=NC2=C1NC1=CC=C(Cl)C=C1 KJGSMDDJESIJNG-UHFFFAOYSA-N 0.000 claims description 4
- XUIHMMWMTLPFOD-UHFFFAOYSA-N 9-(4-chlorophenyl)-6-morpholin-4-ylpurine-2-carbonitrile Chemical compound C1=CC(Cl)=CC=C1N1C2=NC(C#N)=NC(N3CCOCC3)=C2N=C1 XUIHMMWMTLPFOD-UHFFFAOYSA-N 0.000 claims description 4
- 208000002193 Pain Diseases 0.000 claims description 4
- 125000004430 oxygen atom Chemical group O* 0.000 claims description 4
- 125000004434 sulfur atom Chemical group 0.000 claims description 4
- DBYOJBZTUZLETB-UHFFFAOYSA-N 1-(4-methylphenyl)-4-morpholin-4-ylpyrazolo[3,4-d]pyrimidine-6-carbonitrile Chemical compound C1=CC(C)=CC=C1N1C2=NC(C#N)=NC(N3CCOCC3)=C2C=N1 DBYOJBZTUZLETB-UHFFFAOYSA-N 0.000 claims description 3
- OHYNGDSTLQYXLP-UHFFFAOYSA-N 4-(4-chloroanilino)-7-ethylpyrrolo[2,3-d]pyrimidine-2-carbonitrile Chemical compound N1=C(C#N)N=C2N(CC)C=CC2=C1NC1=CC=C(Cl)C=C1 OHYNGDSTLQYXLP-UHFFFAOYSA-N 0.000 claims description 3
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 claims description 3
- ILVKKBYDRWXMGO-UHFFFAOYSA-N 6-(2-aminoethylamino)-9-(4-chlorophenyl)purine-2-carbonitrile Chemical compound C1=NC=2C(NCCN)=NC(C#N)=NC=2N1C1=CC=C(Cl)C=C1 ILVKKBYDRWXMGO-UHFFFAOYSA-N 0.000 claims description 3
- IJLSEYBZVOUGOY-UHFFFAOYSA-N 6-(4-aminopiperidin-1-yl)-9-(4-chlorophenyl)purine-2-carbonitrile Chemical compound C1CC(N)CCN1C1=NC(C#N)=NC2=C1N=CN2C1=CC=C(Cl)C=C1 IJLSEYBZVOUGOY-UHFFFAOYSA-N 0.000 claims description 3
- HIZRIHSRKDKKSH-UHFFFAOYSA-N 6-morpholin-4-yl-9-(4-propan-2-ylphenyl)purine-2-carbonitrile Chemical compound C1=CC(C(C)C)=CC=C1N1C2=NC(C#N)=NC(N3CCOCC3)=C2N=C1 HIZRIHSRKDKKSH-UHFFFAOYSA-N 0.000 claims description 3
- PCLZMBYSLWKOAK-UHFFFAOYSA-N 7-(4-chlorophenyl)-4-(ethylamino)pyrrolo[2,3-d]pyrimidine-2-carbonitrile Chemical compound C1=CC=2C(NCC)=NC(C#N)=NC=2N1C1=CC=C(Cl)C=C1 PCLZMBYSLWKOAK-UHFFFAOYSA-N 0.000 claims description 3
- TUXPZXDUIDXMKS-UHFFFAOYSA-N 7-(4-methoxyphenyl)-4-morpholin-4-yl-5,6-dihydropyrrolo[2,3-d]pyrimidine-2-carbonitrile Chemical compound C1=CC(OC)=CC=C1N1C(N=C(N=C2N3CCOCC3)C#N)=C2CC1 TUXPZXDUIDXMKS-UHFFFAOYSA-N 0.000 claims description 3
- XNGFLKZGUISSFI-UHFFFAOYSA-N 7-(4-methoxyphenyl)-4-pyrrolidin-1-yl-5,6-dihydropyrrolo[2,3-d]pyrimidine-2-carbonitrile Chemical compound C1=CC(OC)=CC=C1N1C(N=C(N=C2N3CCCC3)C#N)=C2CC1 XNGFLKZGUISSFI-UHFFFAOYSA-N 0.000 claims description 3
- SADXVLLLVZNAIE-UHFFFAOYSA-N 8-amino-6-(4-chloroanilino)-9-ethylpurine-2-carbonitrile Chemical compound N1=C(C#N)N=C2N(CC)C(N)=NC2=C1NC1=CC=C(Cl)C=C1 SADXVLLLVZNAIE-UHFFFAOYSA-N 0.000 claims description 3
- YMNMAQWGBPDRTK-UHFFFAOYSA-N 8-amino-9-(4-chlorophenyl)-6-morpholin-4-ylpurine-2-carbonitrile Chemical compound NC1=NC2=C(N3CCOCC3)N=C(C#N)N=C2N1C1=CC=C(Cl)C=C1 YMNMAQWGBPDRTK-UHFFFAOYSA-N 0.000 claims description 3
- BWHVBFJJBFQDHY-UHFFFAOYSA-N 9-(2-chlorophenyl)-6-morpholin-4-ylpurine-2-carbonitrile Chemical compound ClC1=CC=CC=C1N1C2=NC(C#N)=NC(N3CCOCC3)=C2N=C1 BWHVBFJJBFQDHY-UHFFFAOYSA-N 0.000 claims description 3
- MVVBRPYXMOZGKI-UHFFFAOYSA-N 9-(3,4-difluorophenyl)-6-morpholin-4-ylpurine-2-carbonitrile Chemical compound C1=C(F)C(F)=CC=C1N1C2=NC(C#N)=NC(N3CCOCC3)=C2N=C1 MVVBRPYXMOZGKI-UHFFFAOYSA-N 0.000 claims description 3
- VBGBBKIHTJHISX-UHFFFAOYSA-N 9-(3-chlorophenyl)-6-morpholin-4-ylpurine-2-carbonitrile Chemical compound ClC1=CC=CC(N2C3=NC(=NC(=C3N=C2)N2CCOCC2)C#N)=C1 VBGBBKIHTJHISX-UHFFFAOYSA-N 0.000 claims description 3
- JQODVNYFMAKYFL-UHFFFAOYSA-N 9-(4-chlorophenyl)-6-(3-pyrrolidin-1-ylpropylamino)purine-2-carbonitrile Chemical compound C1=CC(Cl)=CC=C1N1C2=NC(C#N)=NC(NCCCN3CCCC3)=C2N=C1 JQODVNYFMAKYFL-UHFFFAOYSA-N 0.000 claims description 3
- IUNJCEDNJBYIJD-UHFFFAOYSA-N 9-(4-chlorophenyl)-6-(4-pyrrolidin-1-ylpiperidin-1-yl)purine-2-carbonitrile Chemical compound C1=CC(Cl)=CC=C1N1C2=NC(C#N)=NC(N3CCC(CC3)N3CCCC3)=C2N=C1 IUNJCEDNJBYIJD-UHFFFAOYSA-N 0.000 claims description 3
- CDHQZBPHQBCKQV-UHFFFAOYSA-N 9-(4-chlorophenyl)-6-(dimethylamino)purine-2-carbonitrile Chemical compound C1=NC=2C(N(C)C)=NC(C#N)=NC=2N1C1=CC=C(Cl)C=C1 CDHQZBPHQBCKQV-UHFFFAOYSA-N 0.000 claims description 3
- RFQMESZAJFZUBR-UHFFFAOYSA-N 9-(4-chlorophenyl)-6-(ethylamino)purine-2-carbonitrile Chemical compound C1=NC=2C(NCC)=NC(C#N)=NC=2N1C1=CC=C(Cl)C=C1 RFQMESZAJFZUBR-UHFFFAOYSA-N 0.000 claims description 3
- UOMTYTKUUJJIBQ-UHFFFAOYSA-N 9-(4-chlorophenyl)-6-piperazin-1-ylpurine-2-carbonitrile Chemical compound C1=CC(Cl)=CC=C1N1C2=NC(C#N)=NC(N3CCNCC3)=C2N=C1 UOMTYTKUUJJIBQ-UHFFFAOYSA-N 0.000 claims description 3
- WIVBKPYLSWPJQG-UHFFFAOYSA-N 9-(4-chlorophenyl)-6-pyrrolidin-1-ylpurine-2-carbonitrile Chemical compound C1=CC(Cl)=CC=C1N1C2=NC(C#N)=NC(N3CCCC3)=C2N=C1 WIVBKPYLSWPJQG-UHFFFAOYSA-N 0.000 claims description 3
- PJKVLYWRACWXQS-UHFFFAOYSA-N 9-(4-chlorophenyl)-8-(dimethylamino)-6-morpholin-4-ylpurine-2-carbonitrile Chemical compound CN(C)C1=NC2=C(N3CCOCC3)N=C(C#N)N=C2N1C1=CC=C(Cl)C=C1 PJKVLYWRACWXQS-UHFFFAOYSA-N 0.000 claims description 3
- SGVMUUDCZGWPHJ-UHFFFAOYSA-N 9-(4-methoxyphenyl)-6-morpholin-4-ylpurine-2-carbonitrile Chemical compound C1=CC(OC)=CC=C1N1C2=NC(C#N)=NC(N3CCOCC3)=C2N=C1 SGVMUUDCZGWPHJ-UHFFFAOYSA-N 0.000 claims description 3
- HOVKNKINGXLBAW-UHFFFAOYSA-N 9-(4-methoxyphenyl)-6-pyrrolidin-1-ylpurine-2-carbonitrile Chemical compound C1=CC(OC)=CC=C1N1C2=NC(C#N)=NC(N3CCCC3)=C2N=C1 HOVKNKINGXLBAW-UHFFFAOYSA-N 0.000 claims description 3
- ZGNVAGDTSYPAJB-UHFFFAOYSA-N 9-(4-methylphenyl)-6-pyrrolidin-1-ylpurine-2-carbonitrile Chemical compound C1=CC(C)=CC=C1N1C2=NC(C#N)=NC(N3CCCC3)=C2N=C1 ZGNVAGDTSYPAJB-UHFFFAOYSA-N 0.000 claims description 3
- GCLKFJUHXFRUKP-UHFFFAOYSA-N 9-(4-methylsulfonylphenyl)-6-morpholin-4-ylpurine-2-carbonitrile Chemical compound C1=CC(S(=O)(=O)C)=CC=C1N1C2=NC(C#N)=NC(N3CCOCC3)=C2N=C1 GCLKFJUHXFRUKP-UHFFFAOYSA-N 0.000 claims description 3
- 241000124008 Mammalia Species 0.000 claims description 3
- 125000005842 heteroatom Chemical group 0.000 claims description 3
- 208000004296 neuralgia Diseases 0.000 claims description 3
- 208000021722 neuropathic pain Diseases 0.000 claims description 3
- WMCPEBXOCLBPGC-UHFFFAOYSA-N 9-(4-chlorophenyl)-6-morpholin-4-yl-8-oxo-7h-purine-2-carbonitrile Chemical compound C1=CC(Cl)=CC=C1N1C(=O)NC2=C(N3CCOCC3)N=C(C#N)N=C21 WMCPEBXOCLBPGC-UHFFFAOYSA-N 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- 230000002401 inhibitory effect Effects 0.000 claims description 2
- 239000012453 solvate Substances 0.000 claims description 2
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 abstract description 55
- 239000003112 inhibitor Substances 0.000 abstract description 4
- 229910052700 potassium Inorganic materials 0.000 abstract description 3
- 229910052731 fluorine Inorganic materials 0.000 abstract description 2
- 239000013037 reversible inhibitor Substances 0.000 abstract description 2
- 239000000126 substance Substances 0.000 abstract 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 114
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 60
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 54
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 45
- 239000000243 solution Substances 0.000 description 36
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 35
- AFABGHUZZDYHJO-UHFFFAOYSA-N 2-Methylpentane Chemical compound CCCC(C)C AFABGHUZZDYHJO-UHFFFAOYSA-N 0.000 description 34
- 238000005160 1H NMR spectroscopy Methods 0.000 description 33
- 239000000047 product Substances 0.000 description 33
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 27
- 239000012044 organic layer Substances 0.000 description 21
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 18
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 18
- 238000004587 chromatography analysis Methods 0.000 description 17
- 239000000377 silicon dioxide Substances 0.000 description 17
- 239000007787 solid Substances 0.000 description 17
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 16
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 16
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 14
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 13
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 12
- 239000002904 solvent Substances 0.000 description 12
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 9
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 9
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 8
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 7
- 235000017557 sodium bicarbonate Nutrition 0.000 description 7
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 7
- 229940001584 sodium metabisulfite Drugs 0.000 description 7
- 235000010262 sodium metabisulphite Nutrition 0.000 description 7
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 6
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 6
- 238000003756 stirring Methods 0.000 description 6
- KXZJHVJKXJLBKO-UHFFFAOYSA-N chembl1408157 Chemical compound N=1C2=CC=CC=C2C(C(=O)O)=CC=1C1=CC=C(O)C=C1 KXZJHVJKXJLBKO-UHFFFAOYSA-N 0.000 description 5
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 4
- 241000282412 Homo Species 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 4
- 239000012267 brine Substances 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 4
- QSNSCYSYFYORTR-UHFFFAOYSA-N 4-chloroaniline Chemical compound NC1=CC=C(Cl)C=C1 QSNSCYSYFYORTR-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 150000001412 amines Chemical class 0.000 description 3
- 239000012043 crude product Substances 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- FEONFRLLHYXTEZ-UHFFFAOYSA-N methyl 2,2-diethoxyacetate Chemical compound CCOC(OCC)C(=O)OC FEONFRLLHYXTEZ-UHFFFAOYSA-N 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- FCEHBMOGCRZNNI-UHFFFAOYSA-N 1-benzothiophene Chemical compound C1=CC=C2SC=CC2=C1 FCEHBMOGCRZNNI-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- 208000024827 Alzheimer disease Diseases 0.000 description 2
- 108010084457 Cathepsins Proteins 0.000 description 2
- 102000005600 Cathepsins Human genes 0.000 description 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 2
- 208000011231 Crohn disease Diseases 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 2
- VLJNHYLEOZPXFW-BYPYZUCNSA-N L-prolinamide Chemical compound NC(=O)[C@@H]1CCCN1 VLJNHYLEOZPXFW-BYPYZUCNSA-N 0.000 description 2
- 102000043131 MHC class II family Human genes 0.000 description 2
- 108091054438 MHC class II family Proteins 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- YGYAWVDWMABLBF-UHFFFAOYSA-N Phosgene Chemical compound ClC(Cl)=O YGYAWVDWMABLBF-UHFFFAOYSA-N 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 description 2
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
- UCKMPCXJQFINFW-UHFFFAOYSA-N Sulphide Chemical compound [S-2] UCKMPCXJQFINFW-UHFFFAOYSA-N 0.000 description 2
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 2
- OKJPEAGHQZHRQV-UHFFFAOYSA-N Triiodomethane Natural products IC(I)I OKJPEAGHQZHRQV-UHFFFAOYSA-N 0.000 description 2
- 125000003342 alkenyl group Chemical group 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- VCOVUYXJMHMVNV-FMYROPPKSA-N benzyl n-[(2s)-1-[[(2s)-1-[[(2s)-5-(diaminomethylideneamino)-1-[(4-methyl-2-oxochromen-7-yl)amino]-1-oxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]carbamate Chemical compound N([C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NC=1C=C2OC(=O)C=C(C)C2=CC=1)C(=O)OCC1=CC=CC=C1 VCOVUYXJMHMVNV-FMYROPPKSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 125000001309 chloro group Chemical group Cl* 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 230000005284 excitation Effects 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 238000007429 general method Methods 0.000 description 2
- 150000004820 halides Chemical class 0.000 description 2
- 125000005843 halogen group Chemical group 0.000 description 2
- JYVHOGDBFNJNMR-UHFFFAOYSA-N hexane;hydrate Chemical compound O.CCCCCC JYVHOGDBFNJNMR-UHFFFAOYSA-N 0.000 description 2
- 208000026278 immune system disease Diseases 0.000 description 2
- 208000027866 inflammatory disease Diseases 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- HVTICUPFWKNHNG-UHFFFAOYSA-N iodoethane Chemical compound CCI HVTICUPFWKNHNG-UHFFFAOYSA-N 0.000 description 2
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 2
- AWJUIBRHMBBTKR-UHFFFAOYSA-N isoquinoline Chemical compound C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 description 2
- 201000006417 multiple sclerosis Diseases 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 description 2
- 238000007363 ring formation reaction Methods 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 150000003457 sulfones Chemical class 0.000 description 2
- 150000003462 sulfoxides Chemical class 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- UMGDCJDMYOKAJW-UHFFFAOYSA-N thiourea Chemical compound NC(N)=S UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 1
- SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 1
- BDNKZNFMNDZQMI-UHFFFAOYSA-N 1,3-diisopropylcarbodiimide Chemical compound CC(C)N=C=NC(C)C BDNKZNFMNDZQMI-UHFFFAOYSA-N 0.000 description 1
- HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 description 1
- RXPZJYKGHXZIEJ-UHFFFAOYSA-N 2,4,6-trichloro-5-prop-2-enylpyrimidine Chemical compound ClC1=NC(Cl)=C(CC=C)C(Cl)=N1 RXPZJYKGHXZIEJ-UHFFFAOYSA-N 0.000 description 1
- KCKPMJHDDVWLLL-UHFFFAOYSA-N 2,4-dichloro-7-(4-chlorophenyl)pyrrolo[2,3-d]pyrimidine Chemical compound C1=CC(Cl)=CC=C1N1C2=NC(Cl)=NC(Cl)=C2C=C1 KCKPMJHDDVWLLL-UHFFFAOYSA-N 0.000 description 1
- RMFWVOLULURGJI-UHFFFAOYSA-N 2,6-dichloro-7h-purine Chemical compound ClC1=NC(Cl)=C2NC=NC2=N1 RMFWVOLULURGJI-UHFFFAOYSA-N 0.000 description 1
- UVBZEMOEZNCZRE-UHFFFAOYSA-N 2-[2,4-dichloro-6-(4-chloroanilino)pyrimidin-5-yl]acetaldehyde Chemical compound C1=CC(Cl)=CC=C1NC1=NC(Cl)=NC(Cl)=C1CC=O UVBZEMOEZNCZRE-UHFFFAOYSA-N 0.000 description 1
- SUHSVYQLBGBINJ-UHFFFAOYSA-N 2-chloro-n-(4-chlorophenyl)-9-ethylpurin-6-amine Chemical compound N1=C(Cl)N=C2N(CC)C=NC2=C1NC1=CC=C(Cl)C=C1 SUHSVYQLBGBINJ-UHFFFAOYSA-N 0.000 description 1
- AKCRQHGQIJBRMN-UHFFFAOYSA-N 2-chloroaniline Chemical compound NC1=CC=CC=C1Cl AKCRQHGQIJBRMN-UHFFFAOYSA-N 0.000 description 1
- JKBKMIKSUBLJRK-UHFFFAOYSA-N 2-propylsulfanylpyrimidine Chemical compound CCCSC1=NC=CC=N1 JKBKMIKSUBLJRK-UHFFFAOYSA-N 0.000 description 1
- ZRXHLJNBNWVNIM-UHFFFAOYSA-N 3-methyl-1-benzofuran Chemical compound C1=CC=C2C(C)=COC2=C1 ZRXHLJNBNWVNIM-UHFFFAOYSA-N 0.000 description 1
- CJJLJBFJNXMANZ-UHFFFAOYSA-N 4,6-dichloro-2-propylsulfanylpyrimidin-5-amine Chemical compound CCCSC1=NC(Cl)=C(N)C(Cl)=N1 CJJLJBFJNXMANZ-UHFFFAOYSA-N 0.000 description 1
- GVPOUARKWLRVJJ-UHFFFAOYSA-N 4,6-dichloro-5-(2-chloroethyl)-2-methylsulfanylpyrimidine Chemical compound CSC1=NC(Cl)=C(CCCl)C(Cl)=N1 GVPOUARKWLRVJJ-UHFFFAOYSA-N 0.000 description 1
- OYYBICKMSRYMGS-UHFFFAOYSA-N 4-(4-chloroanilino)-6-morpholin-4-yl-5-nitropyrimidine-2-carbonitrile Chemical compound N1=C(C#N)N=C(N2CCOCC2)C([N+](=O)[O-])=C1NC1=CC=C(Cl)C=C1 OYYBICKMSRYMGS-UHFFFAOYSA-N 0.000 description 1
- FXDPPWYXCUOWOI-UHFFFAOYSA-N 4-[9-(2-chlorophenyl)-2-propylsulfanylpurin-6-yl]morpholine Chemical compound C=12N=CN(C=3C(=CC=CC=3)Cl)C2=NC(SCCC)=NC=1N1CCOCC1 FXDPPWYXCUOWOI-UHFFFAOYSA-N 0.000 description 1
- PMJAYWWFCGPNMX-UHFFFAOYSA-N 4-[9-(2-chlorophenyl)-2-propylsulfonylpurin-6-yl]morpholine Chemical compound C=12N=CN(C=3C(=CC=CC=3)Cl)C2=NC(S(=O)(=O)CCC)=NC=1N1CCOCC1 PMJAYWWFCGPNMX-UHFFFAOYSA-N 0.000 description 1
- WEGGBXZHIWVHOI-UHFFFAOYSA-N 4-chloro-2-methylsulfanyl-7h-pyrrolo[2,3-d]pyrimidine Chemical compound CSC1=NC(Cl)=C2C=CNC2=N1 WEGGBXZHIWVHOI-UHFFFAOYSA-N 0.000 description 1
- XQKBYZWMUFUNMD-UHFFFAOYSA-N 4-chloro-7-(4-chlorophenyl)-2-methylsulfanyl-5,6-dihydropyrrolo[2,3-d]pyrimidine Chemical compound C1CC=2C(Cl)=NC(SC)=NC=2N1C1=CC=C(Cl)C=C1 XQKBYZWMUFUNMD-UHFFFAOYSA-N 0.000 description 1
- FYVWMQMPTRZETB-UHFFFAOYSA-N 4-chloro-7-(4-chlorophenyl)-2-methylsulfonyl-5,6-dihydropyrrolo[2,3-d]pyrimidine Chemical compound C1CC=2C(Cl)=NC(S(=O)(=O)C)=NC=2N1C1=CC=C(Cl)C=C1 FYVWMQMPTRZETB-UHFFFAOYSA-N 0.000 description 1
- UGDSPYONQTWGFF-UHFFFAOYSA-N 4-chloro-7-(4-chlorophenyl)-5,6-dihydropyrrolo[2,3-d]pyrimidine-2-carbonitrile Chemical compound C1=CC(Cl)=CC=C1N1C(N=C(N=C2Cl)C#N)=C2CC1 UGDSPYONQTWGFF-UHFFFAOYSA-N 0.000 description 1
- SATHXOVBIHGCRP-UHFFFAOYSA-N 5-(2-hydroxyethyl)-2-methylsulfanyl-1h-pyrimidine-4,6-dione Chemical compound CSC1=NC(=O)C(CCO)C(=O)N1 SATHXOVBIHGCRP-UHFFFAOYSA-N 0.000 description 1
- CREXWCGCJMGNGJ-UHFFFAOYSA-N 5-(2-hydroxyethyl)-2-sulfanylidene-1,3-diazinane-4,6-dione Chemical compound OCCC1C(=O)NC(=S)NC1=O CREXWCGCJMGNGJ-UHFFFAOYSA-N 0.000 description 1
- GJHNZJNXSKYROP-UHFFFAOYSA-N 5-amino-4-(4-chloroanilino)-6-morpholin-4-ylpyrimidine-2-carbonitrile Chemical compound N1=C(C#N)N=C(N2CCOCC2)C(N)=C1NC1=CC=C(Cl)C=C1 GJHNZJNXSKYROP-UHFFFAOYSA-N 0.000 description 1
- UXSILEJMSZDVHE-UHFFFAOYSA-N 6-chloro-9-(4-chlorophenyl)-2-propylsulfonylpurine Chemical compound C12=NC(S(=O)(=O)CCC)=NC(Cl)=C2N=CN1C1=CC=C(Cl)C=C1 UXSILEJMSZDVHE-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
- 239000005695 Ammonium acetate Substances 0.000 description 1
- 208000006386 Bone Resorption Diseases 0.000 description 1
- 229920000623 Cellulose acetate phthalate Polymers 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- XFXPMWWXUTWYJX-UHFFFAOYSA-N Cyanide Chemical compound N#[C-] XFXPMWWXUTWYJX-UHFFFAOYSA-N 0.000 description 1
- 102000016942 Elastin Human genes 0.000 description 1
- 108010014258 Elastin Proteins 0.000 description 1
- 206010014561 Emphysema Diseases 0.000 description 1
- 108060003393 Granulin Proteins 0.000 description 1
- LFTLOKWAGJYHHR-UHFFFAOYSA-N N-methylmorpholine N-oxide Chemical compound CN1(=O)CCOCC1 LFTLOKWAGJYHHR-UHFFFAOYSA-N 0.000 description 1
- JOGFNWIIHMCVBB-UHFFFAOYSA-N N1CCOCC1.ClC1=CC=C(C=C1)NC1=NC(=NC(=C1[N+](=O)[O-])N1CCOCC1)SCCC Chemical compound N1CCOCC1.ClC1=CC=C(C=C1)NC1=NC(=NC(=C1[N+](=O)[O-])N1CCOCC1)SCCC JOGFNWIIHMCVBB-UHFFFAOYSA-N 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 description 1
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 1
- 108090000526 Papain Proteins 0.000 description 1
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Natural products NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 229960000583 acetic acid Drugs 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 235000019257 ammonium acetate Nutrition 0.000 description 1
- 229940043376 ammonium acetate Drugs 0.000 description 1
- 230000030741 antigen processing and presentation Effects 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- RFRXIWQYSOIBDI-UHFFFAOYSA-N benzarone Chemical compound CCC=1OC2=CC=CC=C2C=1C(=O)C1=CC=C(O)C=C1 RFRXIWQYSOIBDI-UHFFFAOYSA-N 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000002805 bone matrix Anatomy 0.000 description 1
- 230000024279 bone resorption Effects 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 229940081734 cellulose acetate phthalate Drugs 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 239000008139 complexing agent Substances 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000007333 cyanation reaction Methods 0.000 description 1
- 238000010908 decantation Methods 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- BGRWYRAHAFMIBJ-UHFFFAOYSA-N diisopropylcarbodiimide Natural products CC(C)NC(=O)NC(C)C BGRWYRAHAFMIBJ-UHFFFAOYSA-N 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 229920002549 elastin Polymers 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000002866 fluorescence resonance energy transfer Methods 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- ACKFDYCQCBEDNU-UHFFFAOYSA-J lead(2+);tetraacetate Chemical compound [Pb+2].CC([O-])=O.CC([O-])=O.CC([O-])=O.CC([O-])=O ACKFDYCQCBEDNU-UHFFFAOYSA-J 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- LULAYUGMBFYYEX-UHFFFAOYSA-N metachloroperbenzoic acid Natural products OC(=O)C1=CC=CC(Cl)=C1 LULAYUGMBFYYEX-UHFFFAOYSA-N 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- PHWISQNXPLXQRU-UHFFFAOYSA-N n,n-dimethylcarbamothioyl chloride Chemical compound CN(C)C(Cl)=S PHWISQNXPLXQRU-UHFFFAOYSA-N 0.000 description 1
- SAPXQPRWYUQUQQ-UHFFFAOYSA-N n-(2-chlorophenyl)-6-morpholin-4-yl-5-nitro-2-propylsulfanylpyrimidin-4-amine Chemical compound [O-][N+](=O)C=1C(N2CCOCC2)=NC(SCCC)=NC=1NC1=CC=CC=C1Cl SAPXQPRWYUQUQQ-UHFFFAOYSA-N 0.000 description 1
- SJBZJMBEANVQDC-UHFFFAOYSA-N n-(4-chlorophenyl)-7-ethyl-2-methylsulfanylpyrrolo[2,3-d]pyrimidin-4-amine Chemical compound N1=C(SC)N=C2N(CC)C=CC2=C1NC1=CC=C(Cl)C=C1 SJBZJMBEANVQDC-UHFFFAOYSA-N 0.000 description 1
- SIDVENLOGUQLCJ-UHFFFAOYSA-N n-(4-chlorophenyl)-7-ethyl-2-methylsulfonylpyrrolo[2,3-d]pyrimidin-4-amine Chemical compound N1=C(S(C)(=O)=O)N=C2N(CC)C=CC2=C1NC1=CC=C(Cl)C=C1 SIDVENLOGUQLCJ-UHFFFAOYSA-N 0.000 description 1
- ZTYPQOOTXXPFFN-UHFFFAOYSA-N n-(4-chlorophenyl)-9-ethyl-2-methylsulfanylpurin-6-amine Chemical compound N1=C(SC)N=C2N(CC)C=NC2=C1NC1=CC=C(Cl)C=C1 ZTYPQOOTXXPFFN-UHFFFAOYSA-N 0.000 description 1
- ZWDUMYSDRYHNAN-UHFFFAOYSA-N n-(4-chlorophenyl)-9-ethyl-2-methylsulfonylpurin-6-amine Chemical compound N1=C(S(C)(=O)=O)N=C2N(CC)C=NC2=C1NC1=CC=C(Cl)C=C1 ZWDUMYSDRYHNAN-UHFFFAOYSA-N 0.000 description 1
- KUDPGZONDFORKU-UHFFFAOYSA-N n-chloroaniline Chemical compound ClNC1=CC=CC=C1 KUDPGZONDFORKU-UHFFFAOYSA-N 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000012285 osmium tetroxide Substances 0.000 description 1
- 229910000489 osmium tetroxide Inorganic materials 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 235000019834 papain Nutrition 0.000 description 1
- 229940055729 papain Drugs 0.000 description 1
- 150000004965 peroxy acids Chemical class 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- NNFCIKHAZHQZJG-UHFFFAOYSA-N potassium cyanide Chemical compound [K+].N#[C-] NNFCIKHAZHQZJG-UHFFFAOYSA-N 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical compound C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 229910000104 sodium hydride Inorganic materials 0.000 description 1
- RMBAVIFYHOYIFM-UHFFFAOYSA-M sodium methanethiolate Chemical compound [Na+].[S-]C RMBAVIFYHOYIFM-UHFFFAOYSA-M 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 229930192474 thiophene Natural products 0.000 description 1
- ODLHGICHYURWBS-LKONHMLTSA-N trappsol cyclo Chemical compound CC(O)COC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)COCC(O)C)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1COCC(C)O ODLHGICHYURWBS-LKONHMLTSA-N 0.000 description 1
- UCPYLLCMEDAXFR-UHFFFAOYSA-N triphosgene Chemical compound ClC(Cl)(Cl)OC(=O)OC(Cl)(Cl)Cl UCPYLLCMEDAXFR-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
- C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Biomedical Technology (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE0201980A SE0201980D0 (sv) | 2002-06-24 | 2002-06-24 | Novel compounds |
| PCT/SE2003/001079 WO2004000843A1 (en) | 2002-06-24 | 2003-06-23 | NOVEL PURINE- OR PYRROLOL[2,3-d]PYRIMIDINE-2-CARBONITILES FOR TREATING DISEASES ASSOCIATED WITH CYSTEINE PROTEASE ACTIVITY |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005533804A true JP2005533804A (ja) | 2005-11-10 |
| JP2005533804A5 JP2005533804A5 (enExample) | 2006-08-10 |
Family
ID=20288336
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004515329A Pending JP2005533804A (ja) | 2002-06-24 | 2003-06-23 | システイン・プロテアーゼ活性に関係する疾患を処置するための新規プリン−もしくはピロール−［２，３−ｄ］ピリミジン−２−カルボニトリル |
Country Status (8)
| Country | Link |
|---|---|
| US (3) | US7439240B2 (enExample) |
| EP (1) | EP1532148B1 (enExample) |
| JP (1) | JP2005533804A (enExample) |
| AU (1) | AU2003243096A1 (enExample) |
| DE (1) | DE60311272T2 (enExample) |
| ES (1) | ES2279162T3 (enExample) |
| SE (1) | SE0201980D0 (enExample) |
| WO (1) | WO2004000843A1 (enExample) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2009523717A (ja) * | 2006-01-16 | 2009-06-25 | ナームローゼ・フエンノートチヤツプ・オルガノン | カテプシンＫおよびＳの阻害剤としての６−フェニル−ＩＨ−イミダゾ［４，５−ｃ］ピリジン−４−カルボニトリル誘導体 |
| WO2009107767A1 (ja) * | 2008-02-29 | 2009-09-03 | 大日本住友製薬株式会社 | Ｈ４受容体アンタゴニスト作用を有する新規２環性ピリミジン誘導体 |
| JP2010533675A (ja) * | 2007-07-16 | 2010-10-28 | ナームローゼ・フエンノートチヤツプ・オルガノン | カテプシン阻害剤としての６−フェニル−１Ｈ−イミダゾ［４，５−ｃ］ピリジン−４−カルボニトリル誘導体 |
| WO2013157562A1 (ja) * | 2012-04-17 | 2013-10-24 | アステラス製薬株式会社 | 含窒素二環式芳香族へテロ環化合物 |
| KR20190073673A (ko) * | 2017-12-19 | 2019-06-27 | 한림제약(주) | 피롤로[2,3-d]피리미딘 유도체 또는 이의 염 및 이를 포함하는 약학 조성물 |
Families Citing this family (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0117396D0 (en) | 2001-07-17 | 2001-09-05 | Glaxo Group Ltd | Chemical compounds |
| AR036375A1 (es) | 2001-08-30 | 2004-09-01 | Novartis Ag | Compuestos pirrolo [2,3-d] pirimidina -2- carbonitrilo, un proceso para su preparacion, una composicion farmaceutica y el uso de dichos compuestos para la preparacion de medicamentos |
| SE0201980D0 (sv) * | 2002-06-24 | 2002-06-24 | Astrazeneca Ab | Novel compounds |
| EP1927594A1 (en) | 2003-01-14 | 2008-06-04 | Arena Pharmaceuticals, Inc. | 1,2,3-Trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia |
| HRP20050696B1 (en) * | 2003-01-14 | 2008-10-31 | Arena Pharmaceuticals Inc. | 1,2,3-trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prpphylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia |
| GB0308208D0 (en) | 2003-04-09 | 2003-05-14 | Glaxo Group Ltd | Chemical compounds |
| AR045047A1 (es) | 2003-07-11 | 2005-10-12 | Arena Pharm Inc | Derivados arilo y heteroarilo trisustituidos como moduladores del metabolismo y de la profilaxis y tratamiento de desordenes relacionados con los mismos |
| US7132426B2 (en) * | 2003-07-14 | 2006-11-07 | Arena Pharmaceuticals, Inc. | Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto |
| US20070197510A1 (en) * | 2004-03-10 | 2007-08-23 | Kazuyuki Ohmoto | Nitriles and medicinal compositions containing the same as the active ingredient |
| TW200614993A (en) | 2004-06-11 | 2006-05-16 | Akzo Nobel Nv | 4-phenyl-pyrimidine-2-carbonitrile derivatives |
| TW200745055A (en) * | 2005-09-23 | 2007-12-16 | Organon Nv | 4-Phenyl-6-substituted-pyrimidine-2-carbonitrile derivatives |
| US7326715B2 (en) | 2005-09-23 | 2008-02-05 | N.V. Organon | 4-Phenyl-6-substituted-pyrimidine-2-carbonitrile derivatives |
| US7687515B2 (en) | 2006-01-17 | 2010-03-30 | N.V. Organon | 6-phenyl-1H-imidazo[4,5-c]pyridine-4-carbonitrile derivatives |
| WO2007148064A1 (en) * | 2006-06-23 | 2007-12-27 | Astrazeneca Ab | Pteridine derivatives and their use as cathespin inhibitors |
| US20090099157A1 (en) * | 2007-02-15 | 2009-04-16 | Ameriks Michael K | Tetrahydro-pyrazolo-pyridine thioether modulators of cathepsin s |
| US20080269241A1 (en) * | 2007-02-15 | 2008-10-30 | Darin Allen | Bicyclic aminopropyl tetrahydro-pyrazolo-pyridine modulators of cathepsin s |
| US20090118274A1 (en) * | 2007-02-15 | 2009-05-07 | Darin Allen | Monocyclic aminopropyl tetrahydro-pyrazolo-pyridine modulators of cathepsin s |
| US20080207683A1 (en) * | 2007-02-15 | 2008-08-28 | Darin Allen | Biaryl-substituted tetrahydro-pyrazolo-pyridine modulators of cathepsin s |
| US20080200454A1 (en) * | 2007-02-15 | 2008-08-21 | Ameriks Michael K | Carbon-linked tetrahydro-pyrazolo-pyridine modulators of cathepsin s |
| EP1972630A1 (en) * | 2007-03-02 | 2008-09-24 | Glaxo Group Limited | Purines as cysteine protease inhibitors |
| EP2118106A1 (en) * | 2007-03-02 | 2009-11-18 | Glaxo Group Limited | Purines as cysteine protease inhibitors |
| US7932251B2 (en) | 2007-07-16 | 2011-04-26 | N.V. Organon | 6-phenyl-1H-imidazo[4,5-c]pyridine-4-carbonitrile derivatives |
| EA019488B1 (ru) * | 2008-04-21 | 2014-04-30 | Лексикон Фармасьютикалз, Инк. | Ингибиторы limk2 и способы их применения |
| WO2010059418A1 (en) * | 2008-11-19 | 2010-05-27 | The Government Of The U.S.A. As Represented By The Secretary Of The Dept. Of Health & Human Services | Substituted triazine and purine compounds, methods of inhibiting cruzain and rhodesain and methods of treating chagas disease and african trypanosomiasis |
| TW201035094A (en) | 2009-01-16 | 2010-10-01 | Organon Nv | 6-phenyl-1H-imidazo[4,5-c]pyridine-4-carbonitrile derivatives |
| US8026236B2 (en) | 2009-01-16 | 2011-09-27 | N.V. Organon | 6-phenyl-1H-imidazo[4,5-c]pyridine-4-carbonitrile derivatives |
| GB0917934D0 (en) | 2009-10-13 | 2009-11-25 | Syngenta Ltd | Herbicidal compounds |
| US9115126B2 (en) | 2010-01-15 | 2015-08-25 | Merck Sharp & Dohme B.V. | 1H-[1,2,3]triazolo[4,5-c]pyridine-4-carbonitrile derivatives |
| MX2013003184A (es) | 2010-09-22 | 2013-06-07 | Arena Pharm Inc | Moduladores del receptor gpr119 y el tratamiento de transtornos relacionados con el mismo. |
| ES2562274T3 (es) | 2010-10-06 | 2016-03-03 | Fundació Institut De Recerca Biomèdica (Irb Barcelona) | Procedimiento para el diagnóstico, pronóstico y tratamiento de metástasis de cáncer de mama |
| EP2650682A1 (en) | 2012-04-09 | 2013-10-16 | Fundació Privada Institut de Recerca Biomèdica | Method for the prognosis and treatment of cancer metastasis |
| ES2705237T3 (es) | 2012-06-06 | 2019-03-22 | Fundacio Inst De Recerca Biomedica Irb Barcelona | Método para el diagnóstico y el pronóstico de metástasis del cáncer de pulmón |
| DK2906718T3 (da) | 2012-10-12 | 2019-07-01 | Inbiomotion Sl | Fremgangsmåde til diagnose, prognose og behandling af prostatakræftmetastase under anvendelse af c-maf |
| US10119171B2 (en) | 2012-10-12 | 2018-11-06 | Inbiomotion S.L. | Method for the diagnosis, prognosis and treatment of prostate cancer metastasis |
| CA2889572C (en) | 2012-11-08 | 2019-03-05 | Pfizer Inc. | Heteroaromatic compounds as dopamine d1 ligands |
| US20160032399A1 (en) | 2013-03-15 | 2016-02-04 | Inbiomotion S.L. | Method for the Prognosis and Treatment of Renal Cell Carcinoma Metastasis |
| AU2014229505B2 (en) | 2013-03-15 | 2020-02-27 | Fundacio Institut De Recerca Biomedica (Irb Barcelona) | Method for the prognosis and treatment of cancer metastasis |
| JP6550045B2 (ja) | 2013-10-09 | 2019-07-24 | フンダシオ、インスティトゥト、デ、レセルカ、ビオメディカ（イエレベ、バルセロナ）Ｆｕｎｄａｃｉｏ Ｉｎｓｔｉｔｕｔ Ｄｅ Ｒｅｃｅｒｃａ Ｂｉｏｍｅｄｉｃａ （Ｉｒｂ Ｂａｒｃｅｌｏｎａ） | 乳がんに由来する骨の転移がんの予後診断および処置のための方法 |
| CA2946990A1 (en) | 2014-04-28 | 2015-11-05 | Pfizer Inc. | Heterocyclic compounds and their use as dopamine d1 ligands |
| SG11201700777VA (en) | 2014-08-04 | 2017-02-27 | Nuevolution As | Optionally fused heterocyclyl-substituted derivatives of pyrimidine useful for the treatment of inflammatory, metabolic, oncologic and autoimmune diseases |
| JP2017538412A (ja) | 2014-12-11 | 2017-12-28 | インバイオモーション エセ．エレ． | ヒトｃ−ｍａｆに対する結合メンバー |
| US11007175B2 (en) | 2015-01-06 | 2021-05-18 | Arena Pharmaceuticals, Inc. | Methods of treating conditions related to the S1P1 receptor |
| BR112017027656B1 (pt) | 2015-06-22 | 2023-12-05 | Arena Pharmaceuticals, Inc. | Hábito cristalino de placa livre de sal de l-arginina de ácido (r)-2-(7-(4- ciclopentil-3-(trifluorometil)benzilóxi)- 1,2,3,4-tetra-hidrociclo-penta[b]indol-3- il)acético, composição farmacêutica que o compreende, seus usos e método de preparação do mesmo |
| CN117230193A (zh) | 2016-05-25 | 2023-12-15 | 生物运动有限公司 | 基于c-maf状态的乳腺癌治疗性治疗 |
| CA3053418A1 (en) | 2017-02-16 | 2018-08-23 | Arena Pharmaceuticals, Inc. | Compounds and methods for treatment of primary biliary cholangitis |
| EP3713581A1 (en) | 2017-11-22 | 2020-09-30 | Inbiomotion S.L. | Therapeutic treatment of breast cancer based on c-maf |
| BR112020024762A2 (pt) | 2018-06-06 | 2021-03-23 | Arena Pharmaceuticals, Inc. | métodos de tratamento de condições relacionadas ao receptor s1p1 |
| WO2020201572A1 (en) | 2019-04-05 | 2020-10-08 | Université De Bretagne Occidentale | Protease-activated receptor-2 inhibitors for the treatment of sensory neuropathy induced by a marine neurotoxic poisoning |
| EP4076661A1 (en) | 2019-12-20 | 2022-10-26 | Nuevolution A/S | Compounds active towards nuclear receptors |
| EP4076657A1 (en) | 2019-12-20 | 2022-10-26 | Nuevolution A/S | Compounds active towards nuclear receptors |
| WO2021198955A1 (en) | 2020-03-31 | 2021-10-07 | Nuevolution A/S | Compounds active towards nuclear receptors |
| EP4126875A1 (en) | 2020-03-31 | 2023-02-08 | Nuevolution A/S | Compounds active towards nuclear receptors |
| WO2024105159A1 (en) * | 2022-11-16 | 2024-05-23 | University Of Zurich | Ligands of the m6a-rna readers |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002000676A1 (en) * | 2000-06-27 | 2002-01-03 | Pfizer Limited | Purine derivatives |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HRP20010738B1 (en) | 1999-03-15 | 2005-02-28 | Axys Pharmaceuticals | N-cyanomethyl amides as protease inhibitors |
| JP2001011037A (ja) * | 1999-07-01 | 2001-01-16 | Kissei Pharmaceut Co Ltd | シクロアルカンカルボン酸アミド誘導体 |
| WO2001044257A1 (en) * | 1999-12-17 | 2001-06-21 | Ariad Pharmaceuticals, Inc. | Proton pump inhibitors |
| HUP0204560A3 (en) * | 2000-02-04 | 2005-03-29 | Pfizer Prod Inc | Heterocyclic amide derivatives and pharmaceutical compositions containing them and their use |
| US6921753B2 (en) * | 2000-06-27 | 2005-07-26 | Pfizer Inc | Purine derivatives |
| JP2004511549A (ja) * | 2000-10-19 | 2004-04-15 | ナエジャ ファーマシューティカル インク | システインプロテアーゼ阻害剤としての新規のジヒドロピリミジン誘導体 |
| GB0121033D0 (en) * | 2001-08-30 | 2001-10-24 | Novartis Ag | Organic compounds |
| AR036375A1 (es) | 2001-08-30 | 2004-09-01 | Novartis Ag | Compuestos pirrolo [2,3-d] pirimidina -2- carbonitrilo, un proceso para su preparacion, una composicion farmaceutica y el uso de dichos compuestos para la preparacion de medicamentos |
| SE0201976D0 (sv) * | 2002-06-24 | 2002-06-24 | Astrazeneca Ab | Novel compounds |
| SE0201980D0 (sv) * | 2002-06-24 | 2002-06-24 | Astrazeneca Ab | Novel compounds |
| GB0220187D0 (en) * | 2002-08-30 | 2002-10-09 | Novartis Ag | Organic compounds |
| AR043692A1 (es) | 2003-02-06 | 2005-08-10 | Novartis Ag | 2-cianopirrolopirimidinas y sus usos farmaceuticos |
| GB0304640D0 (en) | 2003-02-28 | 2003-04-02 | Novartis Ag | Organic compounds |
| US20070197510A1 (en) | 2004-03-10 | 2007-08-23 | Kazuyuki Ohmoto | Nitriles and medicinal compositions containing the same as the active ingredient |
| WO2006040300A1 (en) | 2004-10-12 | 2006-04-20 | N.V. Organon | 4-cycloalkyl-pyrimidine-2-carbonitrile derivatives |
-
2002
- 2002-06-24 SE SE0201980A patent/SE0201980D0/xx unknown
-
2003
- 2003-06-23 DE DE60311272T patent/DE60311272T2/de not_active Expired - Fee Related
- 2003-06-23 AU AU2003243096A patent/AU2003243096A1/en not_active Abandoned
- 2003-06-23 WO PCT/SE2003/001079 patent/WO2004000843A1/en not_active Ceased
- 2003-06-23 ES ES03761002T patent/ES2279162T3/es not_active Expired - Lifetime
- 2003-06-23 JP JP2004515329A patent/JP2005533804A/ja active Pending
- 2003-06-23 EP EP03761002A patent/EP1532148B1/en not_active Expired - Lifetime
- 2003-06-23 US US10/518,815 patent/US7439240B2/en not_active Expired - Fee Related
-
2008
- 2008-02-01 US US12/024,423 patent/US20080119469A1/en not_active Abandoned
- 2008-02-01 US US12/024,375 patent/US20080125426A1/en not_active Abandoned
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002000676A1 (en) * | 2000-06-27 | 2002-01-03 | Pfizer Limited | Purine derivatives |
Cited By (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2009523717A (ja) * | 2006-01-16 | 2009-06-25 | ナームローゼ・フエンノートチヤツプ・オルガノン | カテプシンＫおよびＳの阻害剤としての６−フェニル−ＩＨ−イミダゾ［４，５−ｃ］ピリジン−４−カルボニトリル誘導体 |
| JP2010533675A (ja) * | 2007-07-16 | 2010-10-28 | ナームローゼ・フエンノートチヤツプ・オルガノン | カテプシン阻害剤としての６−フェニル−１Ｈ−イミダゾ［４，５−ｃ］ピリジン−４−カルボニトリル誘導体 |
| WO2009107767A1 (ja) * | 2008-02-29 | 2009-09-03 | 大日本住友製薬株式会社 | Ｈ４受容体アンタゴニスト作用を有する新規２環性ピリミジン誘導体 |
| WO2013157562A1 (ja) * | 2012-04-17 | 2013-10-24 | アステラス製薬株式会社 | 含窒素二環式芳香族へテロ環化合物 |
| JPWO2013157562A1 (ja) * | 2012-04-17 | 2015-12-21 | アステラス製薬株式会社 | 含窒素二環式芳香族へテロ環化合物 |
| US9328118B2 (en) | 2012-04-17 | 2016-05-03 | Astellas Pharma Inc. | Nitrogen-containing bicyclic aromatic heterocyclic compound |
| EA026088B1 (ru) * | 2012-04-17 | 2017-02-28 | Астеллас Фарма Инк. | Азотсодержащее бициклическое ароматическое гетероциклическое соединение |
| US9585889B2 (en) | 2012-04-17 | 2017-03-07 | Astellas Pharma Inc. | Nitrogen-containing bicyclic aromatic heterocyclic compound |
| KR20190073673A (ko) * | 2017-12-19 | 2019-06-27 | 한림제약(주) | 피롤로[2,3-d]피리미딘 유도체 또는 이의 염 및 이를 포함하는 약학 조성물 |
| KR102054910B1 (ko) | 2017-12-19 | 2019-12-12 | 한림제약(주) | 피롤로[2,3-d]피리미딘 유도체 또는 이의 염 및 이를 포함하는 약학 조성물 |
Also Published As
| Publication number | Publication date |
|---|---|
| EP1532148A1 (en) | 2005-05-25 |
| ES2279162T3 (es) | 2007-08-16 |
| US7439240B2 (en) | 2008-10-21 |
| US20050203107A1 (en) | 2005-09-15 |
| WO2004000843A1 (en) | 2003-12-31 |
| SE0201980D0 (sv) | 2002-06-24 |
| DE60311272D1 (de) | 2007-03-08 |
| EP1532148B1 (en) | 2007-01-17 |
| US20080125426A1 (en) | 2008-05-29 |
| US20080119469A1 (en) | 2008-05-22 |
| DE60311272T2 (de) | 2007-11-15 |
| AU2003243096A1 (en) | 2004-01-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US7439240B2 (en) | Purine-or pyrrolol[2,3-d]pyrimidine-2-carbonitiles for treating diseases associated with cysteine protease activity | |
| US7125881B2 (en) | Use of pyrimidine—or triazine—2 carbonitiles for treating diseases associated with cysteine prostease activity and novel pyrimidine-2-carbonitile derivatives | |
| ES2770550T3 (es) | Inhibidores de quinasa | |
| EP4291176A1 (en) | Cdk inhibitors and methods of use thereof | |
| AU2008304417B2 (en) | Polo-like kinase inhibitors | |
| TW201321370A (zh) | 經取代之苄基吲唑 | |
| JP2009529541A (ja) | 代謝性障害治療のための８−ヘテロアリ−ルプリンのｍｎｋ２阻害剤 | |
| AU2012283775A1 (en) | Inhibitors of Bruton's tyrosine kinase | |
| TW201514166A (zh) | 經雜芳基取代之吲唑 | |
| CN119923401A (zh) | 新型四杂环化合物 | |
| KR20190032420A (ko) | Fgfr 억제제로서 사용되는 헤테로시클릭 화합물 | |
| JP2016503049A (ja) | 治療用に活性なピラゾロ−ピリミジン誘導体 | |
| EP3145512A1 (en) | Substituted ethynyl heterobicyclic compounds as tyrosine kinase inhibitors | |
| KR20080002865A (ko) | 피리도[２,３-ｄ]피리미딘-７-온 및３,４-디히드로피리미도[４,５-ｄ]피리미딘-２(１ｈ)-온유도체의 제조 방법 | |
| WO2014100540A1 (en) | Pyrazole substituted imidazopyrazines as casein kinase 1 d/e inhibitors | |
| WO2022140769A1 (en) | Lactam (hetero)arylfusedpyrimidine derivatives as inhibitors of erbb2 | |
| JP6817952B2 (ja) | ピリミジン誘導体 | |
| JP2024534208A (ja) | Ｐａｒｐ７阻害剤及びその使用 | |
| CN111499613A (zh) | N-甲酰胺衍生物、其制备方法及其在医药上的用途 | |
| CN113004282B (zh) | 取代的炔基杂环化合物 | |
| JP2025513321A (ja) | 二環式化合物 | |
| JP2025504495A (ja) | Ｒａｓシグナル伝達の調節因子としての縮合複素環式化合物 | |
| CN103570731B (zh) | 嘧啶并三环或嘧啶并四环类化合物及其药用组合物和应用 | |
| CN117916235A (zh) | 周期蛋白依赖性激酶抑制剂 | |
| ES2771151T3 (es) | Derivados de piperidina como inhibidor de señalización wnt |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20060621 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20060621 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20100119 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20100615 |